Lipella Pharmaceuticals (LIPO) announced that U.S. Patent No. 12,138,345 for its proprietary liposomal drug delivery platform will be officially issued by the U.S. Patent and Trademark Office, or ...
Allowance provides broad IP protection for drug-delivery platform and extends market exclusivity for two lead clinical assets currently in Phase 2 trials PITTSBURGH, Oct. 15, 2024 (GLOBE NEWSWIRE) -- ...
CD Formulation has recently introduced liposome formulations, which are remarkably better at absorption, stability, and release. NY, UNITED STATES, December 13, 2024 ...
Chalet Tan is a professor in the Department of Pharmaceutical Sciences at the University of Tennessee Health Science Center (TN, USA). Her lab focuses on targeted drug delivery, specifically biologics ...
Liposomes were formulated for the first time at the beginning of the 1960s, exosomes were named as such at the beginning of the 1980s. Liposomes have been extensively explored as a drug delivery ...
As part of the first-in-human trial, participants received more than 15 times the standard dose of the chemotherapy drug doxorubicin every 21 days for up to one year. “Usually, a patient can only ...
Comprehensive Analysis Examines Liposomal NMN Delivery, Dosage Research Context, Third-Party Verification Standards, and What ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback